Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1R | P00736 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | F3 | P13726 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | KIF20B | Q96Q89 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | JUN | P05412 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14690650 | 0.86 | NT5E (0.50) | C1RKDM4EBACE1NT5EESR1 | |
| SCHEMBL3826784 | 0.86 | NT5E (0.54) | C1RKDM4EBACE1PARP1F7 | |
| SCHEMBL8396844 | 0.84 | C1R (0.45) | C1RKDM4EBACE1PARP1F7 | |
| SCHEMBL9493259 | 0.83 | C1R (0.50) | C1RKDM4EBACE1PARP1F7 | |
| SCHEMBL900362 | 0.83 | MAPT (0.51) | C1RKDM4EPARP1F7F3 | |
| SCHEMBL26998811 | 0.82 | HRH4 (0.40) | KDM4EHSD17B10LMNACYP3A4CYP2C19 | |
| SCHEMBL3925464 | 0.79 | C1R (0.41) | C1RKDM4EBACE1PARP1F7 | |
| SCHEMBL9493411 | 0.76 | NT5E (0.51) | C1RKDM4EPARP1F7F3 | |
| SCHEMBL30827901 | 0.76 | ACHE (0.42) | KDM4EBACE1NT5E | |
| SCHEMBL23202854 | 0.76 | ACHE (0.42) | KDM4EBACE1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042737-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12281078-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-04-10 | — | — | US | disclosed |
| EP-4486734-A1 | QUINOLINE CGAS ANTAGONIST COMPOUNDS | Immunesensor Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| CN-119137112-A | Quinoline cGAS antagonist compounds | 免疫传感器治疗股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-12134609-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-12091387-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-03-21 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-4208452-A1 | QUINOLINE CGAS ANTAGONIST COMPOUNDS | Immunesensor Therapeutics, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-116234802-A | Quinoline CGAS antagonist compounds | 免疫传感器治疗股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230081291-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| WO-2022051634-A1 | QUINOLINE CGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2021042046-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115579-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | C1R 4582/4885KDM4E 4338/4885BACE1 806/4885 |
| US-12091387-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | C1R 4582/4885KDM4E 4338/4885BACE1 806/4885 |
| US-20260042737-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, SSB, NT5C2 | C1R 1058/4885KDM4E 4220/4885BACE1 2995/4885 |
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | C1R 4582/4885KDM4E 4338/4885BACE1 806/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | C1R 4582/4885KDM4E 4338/4885BACE1 806/4885 |
| US-12134609-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | C1R 4582/4885KDM4E 4338/4885BACE1 806/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | C1R 4582/4885KDM4E 4338/4885BACE1 806/4885 |
| US-12281078-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | C1R 4582/4885KDM4E 4338/4885BACE1 806/4885 |
| US-20230081291-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | C1R 4582/4885KDM4E 4338/4885BACE1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.